Stifel Maintains Neurogene(NGNE.US) With Buy Rating, Raises Target Price to $46

Futu News11:31 · Ratings

TD Cowen Maintains Neurogene(NGNE.US) With Buy Rating

Futu News08:31 · Ratings

Neurogene's Resilient Clinical Progress and Strong Financial Position Support Buy Rating

TipRanks08:15 · Ratings

Neurogene Is Maintained at Outperform by BMO Capital

Dow JonesNov 20 22:17 · Ratings

Neurogene Inc. Faces Uncertainty With NGN-101 Program Amid FDA Challenges and Strategic Hurdles

TipRanksNov 20 14:00

BMO Capital Maintains Neurogene(NGNE.US) With Buy Rating, Cuts Target Price to $60

Futu NewsNov 19 21:31 · Ratings